Abstract
Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays, including Oncotype DX, are expensive and not covered by insurance in some countries Methods: In this study, we retrospectively analyzed a series of 155 patients with estrogen receptor-positive primary BC for whom an Oncotype DX assay was performed between January 2016 and August 2021. The patients’ modified immunohistochemical marker (mIHC4) scores were calculated on the basis of their pathological reports. The correlations of the RS with the online tool PREDICT and mIHC4 scores were evaluated. Results: Of the patients, 43.9% were premenopausal, 147 (94.8%) had T1 or T2 tumor, and 55.5% had no positive lymph nodes. Low (0–10), intermediate (11–25), and high RSs (26–100) were obtained in 16.1%, 61.9%, and 21.9% of the patients, respectively. The RS showed no correlation with the PREDICT score (r = 0.2720) but correlated with the mIHC4 score (r = 0.6356). In addition, a stronger correlation was observed in the patients with no node involvement and in the postmenopausal patients (r = 0.6609 and r = 0.7277, respectively). Conclusions: A relatively strong correlation was observed between the RS and the mIHC4 score. The mIHC4 score is a potentially easy and useful tool to guide adjuvant chemotherapy decision making, especially for postmenopausal patients with no node involvement if a genomic test could not be performed for some reason.
References
1.
Paik
S
, Shak
S
, Tang
G
, Kim
C
, Baker
J
, Cronin
M
, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
. N Engl J Med
. 2004
;351
(27
):2817
–26
.2.
Habel
LA
, Shak
S
, Jacobs
MK
, Capra
A
, Alexander
C
, Pho
M
, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
. Breast Cancer Res
. 2006
;8
(3
):R25
.3.
van de Vijver
MJ
, He
YD
, vanʼt Veer
LJ
, Dai
H
, Hart
AA
, Voskuil
DW
, A gene-expression signature as a predictor of survival in breast cancer
. N Engl J Med
. 2002
;347
(25
):1999
–2009
.4.
van't Veer
LJ
, Paik
S
, Hayes
DF
. Gene expression profiling of breast cancer: a new tumor marker
. J Clin Oncol
. 2005
;23
(8
):1631
–5
. .5.
Kwa
M
, Makris
A
, Esteva
FJ
. Clinical utility of gene-expression signatures in early stage breast cancer
. Nat Rev Clin Oncol
. 2017
;14
(10
):595
–610
. .6.
Harris
LN
, Ismaila
N
, McShane
LM
, Andre
F
, Collyar
DE
, Gonzalez-Angulo
AM
, Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline
. J Clin Oncol
. 2016
;34
(10
):1134
–50
.7.
Wishart
GC
, Azzato
EM
, Greenberg
DC
, Rashbass
J
, Kearins
O
, Lawrence
G
, PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
. Breast Cancer Res
. 2010
;12
(1
):R1
.8.
Cuzick
J
, Dowsett
M
, Pineda
S
, Wale
C
, Salter
J
, Quinn
E
, Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic Health recurrence score in early breast cancer
. J Clin Oncol
. 2011
;29
(32
):4273
–8
.9.
Sestak
I
, Dowsett
M
, Ferree
S
, Baehner
FL
, Cuzick
J
. Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
. Breast Cancer Res Treat
. 2016
;159
(1
):71
–8
. .10.
Sestak
I
, Dowsett
M
, Zabaglo
L
, Lopez-Knowles
E
, Ferree
S
, Cowens
JW
, Factors predicting late recurrence for estrogen receptor-positive breast cancer
. J Ntl Cancer Inst
. 2013
;105
(19
):1504
–11
.11.
Sgroi
DC
, Sestak
I
, Cuzick
J
, Zhang
Y
, Schnabel
CA
, Schroeder
B
, Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
. Lancet Oncol
. 2013
;14
(11
):1067
–76
.12.
Dowsett
M
, Sestak
I
, Lopez-Knowles
E
, Sidhu
K
, Dunbier
AK
, Cowens
JW
, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
. J Clin Oncol
. 2013
;31
(22
):2783
–90
.13.
Bartlett
JM
, Christiansen
J
, Gustavson
M
, Rimm
DL
, Piper
T
, van de Velde
CJ
, Validation of the IHC4 breast cancer prognostic algorithm using multiple approaches on the multinational TEAM clinical trial
. Arch Pathol Lab Med
. 2016
;140
(1
):66
–74
.14.
Abubakar
M
, Figueroa
J
, Ali
HR
, Blows
F
, Lissowska
J
, Caldas
C
, Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
. Mod Pathol
. 2019
;32
(9
):1244
–56
.15.
Jin
L
, Chen
K
, Tan
C
, Li
J
, Luo
J
, Yang
Y
, Prognostic value of modified IHC4 score in patients with estrogen receptor-positive metastatic breast cancer
. Oncologist
. 2020
;25
(8
):e1170
–80
.16.
Elsamany
S
, Elmorsy
S
, Alzahrani
A
, Rasmy
A
, Abozeed
WN
, Mohammed
AA
, Predictive value of IHC4 score for pathological response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer
. Asian Pac J Cancer Prev
. 2015
;16
(17
):7975
–9
.17.
Ma
H
, Lu
Y
, Marchbanks
PA
, Folger
SG
, Strom
BL
, McDonald
JA
, Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women
. Breast Cancer Res
. 2013
;15
(5
):R90
.18.
Candido dos Reis
FJ
, Wishart
GC
, Dicks
EM
, Greenberg
D
, Rashbass
J
, Schmidt
MK
, An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation
. Breast Cancer Res
. 2017
;19
(1
):58
.19.
Sparano
JA
, Crager
MR
, Tang
G
, Gray
RJ
, Stemmer
SM
, Shak
S
. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer
. J Clin Oncol
. 2021
;39
(6
):557
–64
. .20.
Barton
S
, Zabaglo
L
, AʼHern
R
, Turner
N
, Ferguson
T
, OʼNeill
S
, Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
. Br J Cancer
. 2012
;106
(11
):1760
–5
.21.
Dodson
A
, Zabaglo
L
, Yeo
B
, Miller
K
, Smith
I
, Dowsett
M
. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study
. J Clin Pathol
. 2016
;69
(2
):128
–35
. .22.
Lakhanpal
R
, Sestak
I
, Shadbolt
B
, Bennett
GM
, Brown
M
, Phillips
T
, IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer
. Breast
. 2016
;29
:147
–52
.23.
Park
YH
, Im
SA
, Cho
EY
, Ahn
JH
, Woo
SY
, Kim
S
, Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers
. Oncology
. 2014
;86
(5–6
):279
–88
.24.
Yeo
B
, Zabaglo
L
, Hills
M
, Dodson
A
, Smith
I
, Dowsett
M
. Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
. Br J Cancer
. 2015
;113
(3
):390
–5
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
